Latest Breaking News On - ஜநரல் ஊட்டச்சத்து நிறுவனம் - Page 1 : comparemela.com
Natural Alternatives International, Inc. Announces 2021 Q4 and YTD Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Protein Supplement Market to manifest the fastest CAGR of 7.4% through 2025
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Protein Supplement Market to manifest the fastest CAGR of 7.4% through 2025
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Cardax Reports Q1 2021 Results
- Operating loss decreased vs. Q1 2020
- Net loss increased vs. Q1 2020
- ZanthoSyn® revenues decreased vs. Q1 2020
- Company pursuing multiple funding opportunities
News provided by
Share this article
HONOLULU, May 14, 2021 /PRNewswire/ Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights:
Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 primarily due to reduced salaries & wages, professional fees, stock based compensation, and selling, general, & administrative expenses. Other expenses increased from $96,837 in Q1 2020 to $610,806 in Q1 2021, primarily due to a non-cash reduction in the gain from modification of debt instruments and a non-cash change in the fair value of the derivative liability. Net loss increased from $1,002,868 in Q1 2020 to $1,382,118 in Q1 2021.
Cardax Reports 2020 Results
- ZanthoSyn® revenues decreased vs. 2019
- Company pursuing multiple funding opportunities
- CHASE study recruitment suspended due to COVID-19
- COVID-19 clinical trial grant application progresses
News provided by
Share this article
HONOLULU, April 15, 2021 /PRNewswire/ Cardax, Inc. (OTCQB:CDXI) reported its 2020 results. Highlights:
Financial Results. Net loss for 2020 decreased from $5,093,037 in 2019 to $5,055,507 in 2020. Operating expenses decreased from $4,442,659 in 2019 to $3,405,452 in 2020, primarily due to reduced professional fees, research & development, salaries & wages, and selling, general, & administrative expenses. Other expenses increased from $1,015,934 in 2019 to $1,992,871 in 2020, primarily due to non-cash debt discounts related to outstanding convertible notes.
ZanthoSyn® Sales. Cardax net revenues from ZanthoSyn®, the Company s astaxanthin dietary supplement, decreased from $710,949 in 2019 to $538,946 in 2020, resu